## RARE: Ultragenyx Pharmaceutical Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -4.8% below STRENGTH zone (3.0-6.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-7.1% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($30.48)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 2 ($0.36M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.5% (-0.8%)
- JPMORGAN CHASE & CO: 8.3% (+146.0%)
- FMR, LLC: 7.6% (+179.6%)
- Blackrock Inc.: 6.7% (+2.7%)
- Sands Capital Manage: 3.9% (-4.4%)

### Key Risks

1. Momentum deterioration: MRS_10 falling (-7.1% 5d) with bearish MACD, trend may be turning.
2. Elevated short interest (9.5%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Revenue growth strong at 21% YoY. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $3.2B |
| Beta | 0.16 |
| 52W Range | $25.81 - $46.50 |
| Short Interest | 9.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | -0.24 |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_10 deteriorating from 2.3% to -4.8% (-7.1% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 7.8pp (needs >3.0% for momentum thesis). Underperforming sector by 4.7pp, stock-specific weakness. Below SMA200 (1.00x), long-term trend not supportive. RSI neutral at 46. OFD pattern: +MUH (Resistance test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -4.76% (CS: 5) | Weak |
| RSI_14 | 45.5 | Neutral |
| MACD Histogram | -0.38 | Bearish |
| vs SMA20 | 0.963x | Below |
| vs SMA50 | 0.993x | Below |
| vs SMA200 | 0.998x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $33.50
- **Stop Loss:** $30.48 (9.0% risk)
- **Target:** $36.52 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 397
- **Position Value:** $13,299.50
- **Portfolio %:** 13.30%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite as VIX falls to 6th percentile and tech rally resumes on AI infrastructure demand. Fed pause expectations from cooling CPI data support equities, though elevated put/call ratio suggests cautious positioning. Focus on quality names in AI-exposed sectors.*

### Earnings

**Next:** 2026-02-12 (Est: $-1.23)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.21 | $-1.81 | -49.7% |
| 2025Q2 | $-1.32 | $-1.17 | +11.4% |
| 2025Q1 | $-1.64 | $-1.57 | +4.4% |
| 2024Q4 | $-1.27 | $-1.39 | -9.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*